Abstract 1527
Background
Cancer patients in good general condition can receive aggressive anti-cancer treatment, while palliative care is most appropriate for advanced cancer patients. In China, patients admit to 3A hospitals regardless of the disease stage. Given the limited number of 3A hospital beds, high price, low quality of life, family sickbed is emerging. With one-to-one help of The Second Affiliated Hospital of FMU, Dongshi Township Health Center (DTHC) established the first family sickbed project for oncology patients (FSOP) in China.
Methods
A retrospective survey was adopted to analyze the general clinical data of patients, hospitalization days and expenses, the types of medical insurance and the opioid analgesics drugs used of 225 patients. And, we carried out telephone follow-up to collect the data concerning the patient’s survival and satisfaction with FSOP service.
Results
From 2015 to 2017, 225 patients were admitted to FSOP. Of 225 patients, 192 (85.3%) were males and 33 (14.7%) were females with ages from 24 to 91 years. The most common disease categories were lung cancer, esophagus cancer, liver cancer. 216 out of 225 patients purchased the NCMS Insurance. During those 3 years, the average total hospitalization expenses, the average personal expenses, the average personal expenses ratio, the average reimbursement ratio, and the average hospitalization days of all patients were 3824.24yuan, 1195.34yuan, 34.64%, 65.37% and 11.79 days, respectively. 51 out of 225 patients suffered pain and needed to eat painkillers. The use of Morphine tablets and OxyContin increased year by year, conforming to the principle of the WHO’s three-step analgesic ladder. Follow-up results showed that 37 (18.5%, 37/200) patients were survive, and 177 patients or family members (88.5%, 177/200) were fully satisfied with FSOP’s service.
Conclusions
Since 2015, the DTHC has provided considerate home care, resulting in a high level of patient and family members satisfaction. Admitting to FSOP can lower the hospitalization expenses, decrease the burden of economy and life, improve the quality of life, and relieve the pain, both mental and physical. Moreover, FSOP will be a more appropriate place to spend the last days for advanced cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Second Affiliated Hospital of Fujian Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract